Haohai is a high-tech biomedical enterprise focus on the research and development, manufacturing and sales of biomedical materials. We strategically target the fast-growing therapeutic areas in the biomedical material market in China, including ophthalmology, medical aesthetics and wound care, orthopedics, anti-adhesion and homostasis.
Haohai focused on investment and mergers and acquisitions opportunities in the global ophthalmic industry and further expanded its ophthalmic business to the field of myopia prevention and control and refractive correction. In addition, the Group also focused on the industrial layout in the field of medical aesthetics, aiming to integrate domestic industrial resources and introduce international advanced innovative technologies and products through various approaches such as R&D, investment, mergers and acquisitions, and cooperation.
In the field of cataract treatment, the Group's R&D projects on various types of IOL are progressing in an orderly manner. Among them, the Group's self-developed casting molded hydrophobic aspheric IOL product has formally commenced clinical trials since September 2020. The clinical trials of the product have started patient enrollment, and the clinical trial period is expected to be approximately two to three years. This casting molded hydrophobic aspheric IOL product adopts innovative production process, which manufactures IOL products from raw material to finished products by injection molding, thus obtaining more accurate optical performance and significant reduction of production costs. The product obtained the European Union CE certificate in January 2021, and can be sold in the member countries of the European Union and related overseas markets.
In the field of myopia prevention, the clinical trials of the Group's new orthokeratology products under development are now progressing in an orderly manner. In addition, the Group is in the process of upgrading the only domestically produced PRL for refractive correction, with the second generation of this product entered the registration process, which will maintain physical aqueous humor circulation and provide a wider range of vision correction.
In the field of ocular surface therapy, the Group's independently developed eye drop, moxifloxacin hydrochloride, was approved by the NMPA in March 2021, and became the first domestic equivalent product, who completed the application and registration for generic drugs.
In the field of fundus therapy, the Group's world-leading R&D projects such as linear cross-linked sodium hyaluronate gel and new artificial vitreous continue to advance steadily. Among them, the product "linear crosslinked sodium hyaluronate gel", which is used to seal retinal cleft and treat rhegmatogenous retinal detachment, has started clinical trials since July 2020.
In the field of medical aesthetics, the Group's third-generation HA Dermal Filler product "Hyalumatrix" with linear particle free characteristics was registered with the NMPA in March 2020 and was launched in August 2020. The Group's domestically-pioneered new generation of organic cross-linked sodium hyaluronate gel product has started clinical trials since November 2020.
In the future, the Group will continue to focus on four fast-growing therapeutic areas, including the existing ophthalmology, medical aesthetics, orthopedics and anti-adhesion and hemostasis, and always aims to continuously improve the quality of life of Chinese people and promote the rehabilitation of patients, by taking differentiated development as its corporate strategy.
|Full name||Shanghai Haohai Biological Technology Co.,Ltd|
|Domicile||No.5 Dongjing Road， Songjiang Industrial Zone， Shanghai, China|
|CSRC Sector||Pharmaceutical manufacturing|
|Has weighted voting rights structure?||No|
|Earnings Per Share||1.30||2.27||2.59|
|R&D expenditure as a % of operating revenue||9.49%||7.24%||6.12%|
|Total Owners' Equity||5734.24||5653.35||3835.45|
|Net Cash Flows-Operating||262.07||348.91||391.29|
|Net Cash Flows-Investing||316.92||-1135.74||-794.64|
|Net Cash Flows-Financing||-190.06||1392.55||-85.33|
|Name||No. of Shares Held (mn)||% of Shares Held|
|HKSCC NOMINEES LIMITED||39.2458||22.15%|
|Shanghai Zhanze Corporate Management Partnership Enterprise (Limited Partnership)||6.471||3.65%|
|Changxing Tonghao Investment Partnership (Limited Partnership)||2.999||1.69%|
All information contained herein is provided by the underlying company itself and is for informational purposes only, and nothing contained herein should be construed as investment advice, either on behalf of a particular security or an overall investment strategy. The Shanghai Stock Exchange does not guarantee its accuracy and reliability and shall under no circumstance be responsible or liable for any error or for any loss directly or indirectly arising from any inaccuracy or omission or from any decision, action or non-action based on or in reliance upon the information herein.
Users may view and download the information herein for personal and non-commercial use free of charge subject to the laws of the People's Republic of China and the Legal Statement. No part of the information herein may be copied, downloaded, stored in a retrieval system or transmitted in any form or by any means, rented, displayed, performed, reproduced, photocopied, altered, sold, broadcast, published or otherwise in whole or in part in any manner for commercial purposes, without the prior written consent of the Shanghai Stock Exchange.
Users are hereby reminded that the Legal Statement represents your legally binding agreement with the Shanghai Stock Exchange. By accessing or using this website, you are also signifying your agreement with and acceptance of all the contents in the Legal Statement. The Shanghai Stock Exchange reserves the right to amend and interpret the Legal Statement.